Akeso's ivonescimab met overall survival endpoint in Phase III trial for EGFR-TKI-resistant NSCLC, with consistent results across Western and...

AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial...

MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal study...

Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in cancer patients.

Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...

TALENTOP's phase 3 data shows liver resection after atezo-bev nearly doubles time to treatment failure in advanced HCC. The...

SPY072 missed its primary endpoint in a rheumatoid arthritis study, narrowing the drug candidate's development path outside inflammatory bowel...

Generate Biomedicines' GB-0895 Phase 1 data released early, showing results in mild-to-moderate asthma and COPD ahead of ERS presentation.

Ivonescimab beats durvalumab in Phase III HARMONi-GI1 trial for biliary tract cancer, meeting primary overall survival endpoint as first-line...

AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.